Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 690

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 6
Chunk 690
---
 assuming the conversion of Convertible Notes and Series B Preferred as of the earliest period reported or at the date
of issuance, if later, but are excluded if their effect is anti-dilutive.

The following table presents common share equivalents
excluded from the calculation of diluted net income (loss) per share for the years ended December 31, 2024 and 2023, as the effect of
their inclusion would have been anti-dilutive during periods of net loss:

    Schedule of anti dilutive shares 

    Year Ended December 31, 2024  
    Year Ended December 31, 2023 

    Convertible Notes 
     1,125,716  
     1,054,508 
  
    Series B Preferred 
     802,786  
     802,786 
  
    Unvested RSUs 
     510,513  
     541,957 
  
    Total 
     2,439,015  
     2,399,251 

Moreover, in connection with an acquisition of Crossflo
by PTSC (see Note 10), 5,690 escrow shares of common stock were issued that are contingent upon certain representations and warranties
made by Crossflo. We exclude these escrow shares from the basic income (loss) per share calculations and would have included the escrowed
shares in the diluted income per share calculations if we reported net income.

Income Taxes

We follow authoritative guidance in accounting for
uncertainties in income taxes. This authoritative guidance prescribes a recognition threshold and measurement requirement for the financial
statement recognition of a tax position that has been taken or is expected to be taken on a tax return and also provides guidance on derecognition,
classification, interest and penalties, accounting in interim periods, disclosure and transition. Under this guidance, we may only recognize
tax positions that meet a “more likely than not” threshold.

We follow authoritative guidance to evaluate whether
a valuation allowance should be established against our deferred tax assets based on the consideration of all available evidence using
a “more likely than not” standard. In making such judgments, significant weight is given to evidence that can be objectively
verified. We assess our deferred tax assets annually under more likely than not scenarios in which they may be realized through future
income.

     F-11 

    Mosaic ImmunoEngineering, Inc.

    Notes to Consolidated Financial Statements
    For the Years Ended December 31,